Key result
Amlodipine restored Cu/ZnSOD expression and activity in hypertensive rat hearts more effectively than enalapril, while enalapril downregulated NADH oxidase activity more.
Why the study?
Does amlodipine reduce oxidative stress in the hearts of stroke-prone spontaneously hypertensive rats compared to enalapril or vehicle?
RCT
randomized
Does amlodipine reduce oxidative stress in the hearts of stroke-prone spontaneously hypertensive rats compared to enalapril or vehicle?
Amlodipine may inhibit vascular remodeling and oxidative stress in hypertensive hearts by upregulating Cu/ZnSOD, suggesting an antiatherogenic antioxidative action beyond blood-pressure lowering.
Answers are grounded in this paper and cite their sources.
May differentially modulate cardiac oxidative stress in hypertensive rats; leaves open translation to human outcomes.
Recent studies have suggested that the calcium antagonists have an antiatherogenic antioxidant property. The effects of the calcium antagonists on reactive oxygen species (ROS)-related enzymes, however, remain unknown. We hypothesized that the calcium antagonists inhibit oxidative stress in the hearts of stroke-prone spontaneously hypertensive rats (SHRSP) through the ROS-scavenging enzymes known as superoxide dismutases (SODs). Male 12-week-old Wister-Kyoto rats (WKY) and SHRSP were used for the study. SHRSP were randomized and treated for 6 weeks with a vehicle, amlodipine (5 mg/kg/day), or enalapril (10 mg/kg/day). NAD(P)H oxidase activity was measured by a luminescence assay, and SOD activity was measured spectrophotometrically. Protein expressions were analyzed by immunoblots. Both drugs showed equipotent effects on systolic blood pressure, left ventricular hypertrophy and fibrosis, the wall-to-lumen ratio, the manganese SOD activity, ROS, and the endothelial NO synthase expression in the SHRSP hearts. Furthermore, amlodipine significantly restored copper/zinc-containing SOD (Cu/ZnSOD) expression and its activity in SHRSP hearts to a level equal to that of WKY more effectively than did enalapril (p <0.05), whereas enalapril downregulated NAD(P)H oxidase activity more than did amlodipine (p <0.05) in the SHRSP hearts. Furthermore, amlodipine restored Cu/ZnSOD expression and its activity in SHRSP hearts to a level equal to that in WKY hearts, and this restoration was significantly more effective than that by enalapril (p <0.05); on the other hand, enalapril induced a greater downregulation of NAD(P)H oxidase activity in SHRSP hearts than did amlodipine (p <0.05). Thus, amlodipine may inhibit vascular remodeling and oxidative stress in the SHRSP heart by efficiently upregulating Cu/ZnSOD, suggesting that the calcium antagonist may exhibit an antiatherogenic antioxidative action beyond blood-pressure lowering through the restoration of Cu/ZnSOD activity in the heart in cases of hypertension.
No takes yet. Share an insight, caveat, or question.
Umemoto et al. (2004) conducted an RCT in hypertension. amlodipine vs. vehicle or enalapril (10 mg/kg/day) was evaluated on Cu/ZnSOD expression and activity (p=<0.05). Amlodipine restored Cu/ZnSOD expression and activity in hypertensive rat hearts more effectively than enalapril, while enalapril downregulated NADH oxidase activity more.
Synapse has enriched 10 related papers. Consider them for comparative context: